References
- Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.
- Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum.2000;43(11):2437–44.
- Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207–18.
- Mayes MD. Race, scleroderma, and survival: why is there a difference? J Rheumatol. 2005; 32(10):1873–4.
- Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, et al. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One. 2014;9(2):e88150.
- Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23(6):1076–84.
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23:581–90.
- LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988;15(2):202–5.
- Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281–5.
- Kuwana M, Sato S, Fau - Kikuchi K, Kikuchi K, Fau - Kawaguchi Y, Kawaguchi Y, Fau - Fujisaku A, Fujisaku A, Fau - Misaki Y, Misaki Y, Fau - Hatamochi A, et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol. 2003;30:1253–8.
- Au K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, et al. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res. 2010;62(12):1772–8.
- Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol.2000;39(6):632–4.
- Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med. 2000;162(1):258–63.